Article ; Online: Immunohistochemical evaluation of biomarkers with predictive role in acromegaly: a literature review.
Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie
2023 Volume 64, Issue 1, Page(s) 25–33
Abstract: Acromegaly is a rare endocrine disorder, which despite the recent advances in diagnosis and management, remains a significant burden in terms of morbidity and mortality for patients because of the frequent aggressive evolution and lack of response to ... ...
| Abstract | Acromegaly is a rare endocrine disorder, which despite the recent advances in diagnosis and management, remains a significant burden in terms of morbidity and mortality for patients because of the frequent aggressive evolution and lack of response to available first-line pharmacological therapy. A switch from the classical "trial and error" management to a personalized therapy approach has been proposed through early identification of biomarkers that could predict treatment response and biological behavior. Several such molecular markers have been extensively studied through immunohistochemistry (IHC), among them the somatostatin receptors type 2 (SSTR-2) and type 5 (SSTR-5), which are known to correlate with response to somatostatin analogues treatment, the SSTR-2 negative tumors usually being resistant to first-generation analogues, while SSTR-5 potentially being a predictive marker for the novel agent, Pasireotide. Based on cytokeratin (CK) immunostaining pattern, somatotropinomas have been classified into densely granulated adenomas (DGAs), which present a milder evolution and favorable outcomes after therapy, and sparsely granulated adenomas (SGAs), known to be more aggressive and frequently resistant to first-line treatment options. Other novel markers, such as the E-cadherin cell-adhesion protein, the aryl hydrocarbon receptor-interacting protein (AIP), the cytoskeleton molecule filamin A (FLNA) and the Ki-67 nuclear antigen have also been the highlight of IHC studies on growth hormone (GH)-producing tumors, with promising results regarding their predictive roles for the outcome of acromegalic patients. In this review, we aimed to summarize the current knowledge on the role of IHC for acromegaly, highlighting the most important biomarkers that could offer valuable information for predicting treatment response, biological behavior, and prognosis. |
|---|---|
| MeSH term(s) | Humans ; Acromegaly ; Adenoma/pathology ; Pituitary Neoplasms ; Biomarkers ; Intracellular Signaling Peptides and Proteins/therapeutic use |
| Chemical Substances | Biomarkers ; Intracellular Signaling Peptides and Proteins |
| Language | English |
| Publishing date | 2023-04-27 |
| Publishing country | Romania |
| Document type | Review ; Journal Article |
| ZDB-ID | 1062519-7 |
| ISSN | 2066-8279 ; 1220-0522 ; 0035-4007 |
| ISSN (online) | 2066-8279 |
| ISSN | 1220-0522 ; 0035-4007 |
| DOI | 10.47162/RJME.64.1.03 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Zs.A 1105: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.